TOPFUND WHERE YOUR MONEY GROWS
Home / Stocks / Artemis Med Service Ltd
ARTEMISMED

Artemis Med Service Ltd Share Price

Live price, chart and which mutual funds hold this stock

TopFund Score: 68/100 · Good See breakdown ↓
…

as of —

₹—

Change

—

Day Open

₹—

Day High

₹—

Day Low

₹—

NSE Close — 25 Sep 2026

₹357.7

Change

+25.0 (7.51%)

Open

₹346.0

Prev. Close

₹332.7

Day High

₹378.8

Day Low

₹346.0

Volume Analysis

Traded

18,980,196

Delivered

1,556,158

Delivery %

8.2%

End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.

Strengths, Weaknesses, Opportunities & Threats

Strengths (0)

No signal for this stock

Weaknesses (1)

  • •Promoter holding is falling

Opportunities (2)

  • •Strong 3-year EPS growth (31.5%)
  • •FII holding has been rising

Threats (0)

No signal for this stock

Rule-based signals from the fundamentals below — not investment advice.

Pivot Levels

Type R3 R2 R1 Pivot S1 S2 S3
Classic ₹408.46 ₹393.63 ₹375.66 ₹360.83 ₹342.86 ₹328.03 ₹310.06
Fibonacci ₹393.63 ₹381.1 ₹373.36 ₹360.83 ₹348.3 ₹340.56 ₹328.03
Camarilla ₹366.72 ₹363.71 ₹360.71 ₹360.83 ₹354.69 ₹351.69 ₹348.68

Support/resistance levels for today, calculated from the previous trading day's high/low/close.

Absolute Returns

YTD

+28.25%

1 Week

+5.5%

1 Month

+12.04%

3 Months

+35.01%

6 Months

+60.72%

1 Year

+54.17%

2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.

Stock Vitals

Computed from the latest available annual financials.

Graham Number

₹93.25

Current price is above the Graham Number — Benjamin Graham's estimate of fair value based on earnings and book value.

DuPont ROE Breakdown

11.9%

Net margin 10.23% × asset turnover 0.76x × equity multiplier 1.53x

Company Overview

Sector

Healthcare

Market Cap

₹5,917 Cr

P/E (TTM)

51.0

ROE

12.0%

Book Value

₹59.0

Face Value

₹1.0

Source: Screener.in (Consolidated figures) — data as of 25 Sep 2026. Not investment advice.

TopFund Analysis

Artemis Med Service Ltd holds up reasonably well on TopFund's composite fundamentals check within the Healthcare sector, at 68/100. The strongest factor is Financial Strength (100/100), while Valuation (11/100) is the weakest area to weigh before deciding. Notably: Promoter holding is falling. Strong 3-year EPS growth (31.5%).

TopFund Score — Fundamentals Quality

68/100 — Good

Data confidence: 79/100 (Moderate Confidence) — based on how complete and how fresh the underlying data is.

As of 27 Sep 2026 · How we calculate this →

Financial Strength

100

Growth

92

Valuation

11

Cash Flow

61

Corporate Governance

55

Momentum

98

Institutional Ownership

62

Business Quality

65

Risk & Volatility

67

Liquidity

50

From Screener.in

  • +Company has delivered good profit growth of 76.6% CAGR over last 5 years
  • −Stock is trading at 5.63 times its book value
  • −Company has a low return on equity of 12.2% over last 3 years.
  • −Promoter holding has decreased over last 3 years: -9.64%

Not investment advice — an automated read of public fundamentals data, for research context only.

Corporate Actions

Announcement under Regulation 30 (LODR)-Credit Rating 24 Sep

CARE reaffirmed Artemis Medicare’s ratings: CARE A Stable for ₹343.15 crore, and CARE A Stable/CARE A2+ for ₹45 crore.

Announcement under Regulation 30 (LODR)-Newspaper Publication 15 Sep

Newspaper Publication for opening of the special window for transfer and dematerialisation of physical securities

Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 08 Sep

Analysts/ Institutional Investors' Conference - September 22, 2026

Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 27 Aug

Analysts/ Institutional Investors' Conference - September 3, 2026

Announcement under Regulation 30 (LODR)-Earnings Call Transcript 10 Aug

Transcript of Earnings Conference Call - Q1 FY27

Source: BSE regulatory filings, via Screener.in.

Quarterly Results

Last several quarters

  Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026
Sales + 210 225 219 225 223 241 232 240 255 275 272 279 287
Expenses + 182 191 186 187 187 199 195 204 214 224 228 228 231
Operating Profit 28 34 33 38 36 42 37 36 41 51 45 52 56
OPM % 13.0% 15.0% 15.0% 17.0% 16.0% 18.0% 16.0% 15.0% 16.0% 18.0% 16.0% 18.0% 20.0%
Other Income + 1 2 2 2 4 7 9 12 7 8 4 8 5
Interest 7 8 8 9 8 8 8 8 7 7 7 6 6
Depreciation 9 10 10 11 11 11 11 12 11 12 12 13 13
Profit before tax 13 19 16 20 22 31 27 29 30 39 30 40 43
Tax % 26.0% 28.0% 29.0% 29.0% 24.0% 28.0% 23.0% 20.0% 29.0% 24.0% 25.0% 25.0% 26.0%
Net Profit + 10 14 12 14 17 22 21 23 21 30 22 30 31
EPS in Rs 1 1 1 1 1 2 2 2 2 2 1 2 2
Raw PDF — — — — — — — — — — — — —

Source: Screener.in — figures in ₹ Crores unless marked %.

Profit & Loss (Yearly)

  Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 TTM
Sales + 547 565 408 555 737 879 937 1,081 1,114
Expenses + 481 503 373 487 643 746 785 893 910
Operating Profit 66 62 35 68 94 133 152 188 203
OPM % 12.0% 11.0% 9.0% 12.0% 13.0% 15.0% 16.0% 17.0% 18.0%
Other Income + 2 4 7 3 7 7 33 27 25
Interest 11 13 13 12 20 31 32 28 27
Depreciation 20 23 22 22 31 40 45 48 50
Profit before tax 37 31 8 37 51 68 108 139 152
Tax % 45.0% 36.0% 18.0% 16.0% 25.0% 28.0% 24.0% 25.0% —
Net Profit + 20 19 6 31 38 49 82 104 114
EPS in Rs 1 1 0 2 3 4 6 7 7
Dividend Payout % 0.0% 0.0% 0.0% 0.0% 16.0% 12.0% 7.0% 7.0% —

Source: Screener.in — figures in ₹ Crores unless marked %.

Balance Sheet

  Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Reserves 280 300 307 346 390 435 824 919
Borrowings + 114 113 147 201 286 320 290 262
Other Liabilities + 147 160 133 149 216 203 229 232
Total Liabilities 554 586 600 710 905 972 1,357 1,429
Fixed Assets + 381 393 383 489 605 719 745 804
CWIP 49 56 81 64 95 33 40 29
Investments 0 0 0 0 0 0 0 0
Other Assets + 124 137 136 157 205 219 572 596
Total Assets 554 586 600 710 905 972 1,357 1,429
Equity Capital 13 13 13 13 13 14 14 16

Source: Screener.in — figures in ₹ Crores unless marked %.

Cash Flow

  Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Cash from Operating Activity + 40 56 27 60 127 109 156 132
Cash from Investing Activity + -50 -26 -37 -107 -158 -88 -393 -90
Cash from Financing Activity + 14 -27 18 44 38 -29 264 -50
Net Cash Flow 5 2 8 -3 7 -8 27 -8
CFO/OP 76 98 83 63 138 94 112 79
Free Cash Flow -17 30 -4 -49 -18 37 65 32

Source: Screener.in — figures in ₹ Crores unless marked %.

Shareholding Pattern

Quarter-by-quarter — Promoters, FII, DII & public holding trend

Promoter holding: 68.03% → 58.39%
  Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026
Public 23.18% 22.72% 22.08% 21.76% 21.93% 20.59% 20.39% 21.45% 21.81% 20.07% 20.37% 20.76%
Promoters 68.03% 68.03% 68.03% 67.51% 67.17% 67.17% 67.17% 66.53% 66.53% 58.38% 58.39% 58.39%
Government 7.18% 7.18% 7.18% 7.12% 7.09% 7.09% 7.09% 7.02% 7.02% 6.16% 6.16% 6.16%
FII 0.09% 0.11% 0.1% 0.16% 0.21% 0.65% 0.31% 0.24% 0.37% 12.47% 12.19% 12.28%
DII 1.51% 1.96% 2.61% 3.45% 3.6% 4.51% 5.04% 4.76% 4.27% 2.91% 2.89% 2.4%

Source: Screener.in — quarterly shareholding disclosures.

Peers Comparison

Healthcare — ranked by market cap

Company Market Cap (Cr) P/E P/B ROE
Artemis Med Service Ltd (this stock) 5,917 51.0 6.34 12.0%
Iol Chem And Pharma Ltd 5,965 33.8 3.31 8.41%
Fdc Limited 5,641 18.3 2.26 11.2%
Senores Pharmaceuticals L 6,241 49.4 6.67 13.4%
Orchid Pharma Limited 6,377 353.0 3.55 1.49%
Gujarat Themis Biosyn Ltd 5,442 112.0 — —
Symbiotec Pharmalab Ltd 6,447 64.8 — 11.7%

Which Mutual Funds Hold Artemis Med Service Ltd?

Frequently Asked Questions about Artemis Med Service Ltd

Community Sentiment

What are other investors saying about Artemis Med Service Ltd?

No votes yet — be the first to share your view.

Sign in to vote

Discussion

User-generated content — not investment advice, and not verified or endorsed by TopFund.

Sign in to join the discussion

No comments yet — start the discussion.